

DAFTAR PUSTAKA

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int (Suppl)*. 2013; 3: 1–150
2. Clarkson MR, Magee C, Brenner BM. Pocket companion to Brenner & Rector's the kidney, 8th edition. Philadelphia: Saunders/Elsevier; 2010. 912.
3. Indonesian Renal Registry. 9th Report of Indonesian Renal Registry 2016. [cited Oktober 2017]. Available at: <http://www.indonesianrenalregistry.org>: 11-12
4. Cai Q, Mukku V, Ahmad M. Coronary Artery Disease in Patients with Chronic Kidney Disease: A Clinical Update. *CCR*. 2014 ; 9(4):331–9.
5. Head SJ, Farooq V, Serruys PW, Kappetein AP. The SYNTAX score and its clinical implications. *Heart*. 2014 ; 100(2):169–77.
6. Ucar H, Mustafa G, Seker T, Durmus Sahin, Kalkan G, Turkoglu C, et al. Impaired kidney function is associated with SYNTAX score in patients with stable coronary artery disease. *Arch Turk Soc Cardiol*. 2014;42(7):621–8.
7. Yan L, Guo L, Zhang F, Gao W. The Relationship Between Kidney Function and Angiographically-Derived SYNTAX Score. *Canadian Journal of Cardiology*. 2011 ;27(6):768–72.
8. Hernandez GT, Sippel M, Mukherjee D. Interrelationship between Chronic Kidney Disease and Risk of Cardio-vascular Diseases. 2013;11:39–40.
9. Go AS, McCulloch CE, Chertow GM, Fan D, Chi-Yuan H. Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization. *The New England Journal of Medicine*. 2004;1296–305.

10. Gomes M, Kirstajn G. Chronic kidney disease: importance of early diagnosis, immediate referral and structured interdisciplinary approach to improve outcomes in patients not yet on dialysis. 2011;33:74–87.
11. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. *Ann Intern Med.* 2003;139(2):137.
12. Stevens LA, Coresh J, Greene T, Levey AS. Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate. *N Engl J Med.* 2006;354(23):2473–83.
13. Kurella M, Lo JC, Chertow GM. Metabolic Syndrome and the Risk for Chronic Kidney Disease among Nondiabetic Adults. *JASN.* 2005;16(7):2134–40.
14. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart Disease and Stroke Statistics—2016 Update. 2015;324.
15. Barquera S, Pedroza-Tobías A, Medina C, Hernández-Barrera L, Bibbins-Domingo K, Lozano R, et al. Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease. *Archives of Medical Research.* 2015;46(5):328–38.
16. Boudoulas KD, Triposkiadis F, Geleris P, Boudoulas H. Coronary Atherosclerosis: Pathophysiologic Basis for Diagnosis and Management. *Progress in Cardiovascular Diseases.* 2016;58(6):676–92.
17. Buja LM. Coronary Artery Disease: Pathological Anatomy and Pathogenesis. In: Willerson JT, Holmes, DR, editors. *Coronary Artery Disease* [Internet].

London: Springer London; 2015 [cited 2020 Oct 17]. 1–20. (Cardiovascular Medicine). Available from: http://link.springer.com/10.1007/978-1-4471-2828-1_1

18. Tanaka S. Novel Insights Into Stenosis on Coronary Angiography—Outline of Functional Assessment of Stable Angina Patients with Angiographic Stenosis. In: Kirac S, editor. *Advances in the Diagnosis of Coronary Atherosclerosis* [Internet]. InTech; 2011 [cited 2020 Oct 17].331–42. Available from: <http://www.intechopen.com/books/advances-in-the-diagnosis-of-coronary-atherosclerosis/novel-insights-into-stenosis-on-coronary-angiography-outline-of-functional-assessment-of-stable-angina>
19. Scanlon PJ, Faxon DP, Ritchie JL, Gibbons RJ. Developed in collaboration with the Society for Cardiac Angiography and Interventions. 1999;33(6):69.
20. Di Lullo L, House A, Gorini A, Santoboni A, Russo D, Ronco C. Chronic kidney disease and cardiovascular complications. *Heart Fail Rev.* 2015;20(3):259–72.
21. Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney International.* 2011;80(6):572–86.
22. Chonchol M, Whittle J, Desbien A, Orner MB, Petersen LA, Kressin NR. Chronic Kidney Disease Is Associated with Angiographic Coronary Artery Disease. *Am J Nephrol.* 2008;28(2):354–60.

23. Sianos G, Morel M-A, Kappetein AP, Morice M-C, Colombo A, Dawkins K, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. *Clinical research*. 2005;219–27.
24. Arumsari D, Artanti KD, Martini S, Widati S. The Description of Smoking Degree Based On BRINKMAN In patient with lung Cancer. 2019 ;7(3):249.
25. Rudjianto A, yuwono agus, shahab alwi, novida hermina. *Konsensus Pengelolaan dan Pencegahan DM Tipe 2*. 1st ed. Jakarta: PB Perkeni; 2015. 11
26. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014;311(5):507.
27. Bhatia S, Arora S, Bhatia SM, Al-Hijji M, Reddy YNV, Patel P, et al. Non–ST-Segment–Elevation Myocardial Infarction Among Patients With Chronic Kidney Disease: A Propensity Score–Matched Comparison of Percutaneous Coronary Intervention Versus Conservative Management. *JAHA*. 2018 ;7(6):1–3.
28. Na KY, Kim CW, Song YR, Chin HJ, Chae D-W. The Association between Kidney Function, Coronary Artery Disease, and Clinical Outcome in Patients Undergoing Coronary Angiography. *J Korean Med Sci*. 2009;24(Suppl 1):87.
29. Cho I, Min H-S, Chun EJ, Park SK, Choi Y, Blumenthal RS, et al. Coronary atherosclerosis detected by coronary CT angiography in asymptomatic subjects with early chronic kidney disease. *Atherosclerosis*. 2010;208(2):406–11.

30. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL, et al. Acute Myocardial Infarction and Renal Dysfunction: A High-Risk Combination. *Ann Intern Med.* 2002;137(7):563.
31. Hachinohe D, Jeong MH, Saito S, Ahmed K, Hwang SH, Lee MG, et al. Management of Non–ST-Segment Elevation Acute Myocardial Infarction in Patients With Chronic Kidney Disease (from the Korea Acute Myocardial Infarction Registry). *The American Journal of Cardiology.* 2011;108(2):206–13.
32. Coskun U, Orta Kilickesmez K, Abaci O, Kocas C, Bostan C, Yildiz A, et al. The Relationship Between Chronic Kidney Disease and SYNTAX Score. *Angiology.* 2011;62(6):504–8.
33. Afsar B, Turkmen K, Covic A, Kanbay M. An Update on Coronary Artery Disease and Chronic Kidney Disease. *International Journal of Nephrology.* 2014;2014:1–9.
34. Serruys PW, Onuma Y, Garg S, Vranckx P, De Bruyne B, Morice M-C, et al. 5-Year Clinical Outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the Sirolimus-Eluting Stent in the Treatment of Patients With Multivessel De Novo Coronary Artery Lesions. *Journal of the American College of Cardiology.* 2010 ;55(11):1093–101.
35. Wenger N. Clinical characteristics of coronary heart disease in women: emphasis on gender differences. *Cardiovascular Research.* 2002;53(3):558–67.

36. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. *American Journal of Kidney Diseases*. 2000;36(3):646–61.
37. Staplin N, Haynes R, Herrington WG, Reith C, Cass A, Fellström B, et al. Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). *American Journal of Kidney Diseases*. 201;68(3):371–80.
38. Orth SR, Hallan SI. Smoking: A Risk Factor for Progression of Chronic Kidney Disease and for Cardiovascular Morbidity and Mortality in Renal Patients—Absence of Evidence or Evidence of Absence?: Figure 1. *CJASN*. 2008;3(1):226–36.
39. Hallan SI, Orth SR. Smoking is a risk factor in the progression to kidney failure. *Kidney International*. 2011;80(5):516–23.
40. Van Laecke S, Van Biesen W. Smoking and chronic kidney disease: seeing the signs through the smoke? *Nephrology Dialysis Transplantation*. 2017;32(3):403–5.
41. Herzog CA. How to Manage the Renal Patient with Coronary Heart Disease: The Agony and the Ecstasy of Opinion-Based Medicine. *Journal of the American Society of Nephrology*. 2003;14(10):2556–72.
42. Gheisari F, Emami M, Raeisi Shahraki H, Samipour S, Nematollahi P. The Role of Gender in the Importance of Risk Factors for Coronary Artery Disease. *Cardiology Research and Practice*. 2020;2020:1–6.

LAMPIRAN



**KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR**



Sekretariat : Lantai 3 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari, MMed, PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 371/UN4.6.4.5.31/PP36/2020

Tanggal: 21 Juli 2020

Dengan Ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH20050217	No Sponsor Protokol	
Peneliti Utama	dr. Eko Irawan Sudarmaji	Sponsor	
Judul Peneliti	Hubungan Antara Laju Filtrasi Glomerulus Dengan Beratnya Penyakit Jantung Koroner Berdasarkan Syntax Score		
No Versi Protokol	2	Tanggal Versi	18 Mei 2020
No Versi PSP	2	Tanggal Versi	18 Mei 2020
Tempat Penelitian	Pusat Jantung Terpadu Rumah Sakit Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard	Masa Berlaku 21 Juli 2020 Sampai 21 Juli 2021	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FK UH	Nama Prof.Dr.dr.Suryani As'ad.,MSc,Sp.GK (K)	Tanda tangan 	Tanggal
Sekretaris Komisi Etik Penelitian Kesehatan FK UH	Nama dr. Agussalim Bukhari, M.Med, PhD, Sp.GK (K)	Tanda tangan 	Tanggal

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan